Talaris Therapeutics is a cell therapy company developing an method of allogeneic hematopoietic stem cell transplantation. Its Facilitated Allo-HSCT Therapy can prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression. The company aims to  transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.